Excessive inflammation contributes to a variety of diseases, including cancer. The class of molecules known as resolvins appears to modify disease progression by decreasing inflammation, offering a potential therapeutic option, according to a recent review article published in the World Journal of Clinical Cases and co-authored by Kazuaki Takabe, MD, PhD, FACS, Clinical Chief of Breast Surgery at Roswell Park Cancer Institute.